ArticleJournal of market access & health policy2023

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.

Alexa C Klimchak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.